neoHIP at #ESMO26
Adding pembrolizumab to neoadjuvant THP increased pCR from 48.3% to 67.2% (+18.9%; p=0.03) in early HER2+ breast cancer.
@OncoAlert #bcsm #BreastCancer
595 浏览 · 15 赞 · 6 转发 · 1 回复
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer
https://esmocongress.esmo.orgSacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgSTARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
https://esmocongress.esmo.orgEfficacy and safety of lifileucel and pembrolizumab in patients with immune check point inhibitor-naïve advanced melanoma: Final results from IOV-COM-202 study
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert Promising, but this was a small phase II trial (n=116). The proposed biomarker strategy remains exploratory, and long-term outcomes are needed. Biomarker-selected immunotherapy is a hypothesis for further testing, not a change in standard practice.
来源：Aya Mohamed | MSc, MD 🎗 · x.com